Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech suit over Amgen's Neupogen alleges patent infringement.

Executive Summary

GENENTECH SUIT OVER AMGEN NEUPOGEN PATENT INFRINGEMENT is an outgrowth of negotiations between the two California biotech giants over the use of recombinant gene technology. The suit, which was filed in San Francisco federal court Oct. 16, claims that Neupogen (filgrastim) uses "vectors, host cells and methods covered by the claims of Genentech's patents."

You may also be interested in...



Genentech, Amgen settle Neupogen dispute

Amgen will make a one-time payment to Genentech as part of a Neupogen and Neulasta patent dispute settlement reached Aug. 26. The terms of the settlement were not disclosed, but Genentech's expectation of a $0.20 per-share impact during the third quarter suggests a payment of approximately $105 mil. after taxes. Both sides have agreed to drop all claims and counterclaims. Amgen said it is not taking a license to any of the three disputed Genentech patents (1"The Pink Sheet" Nov. 11, 1996, T&G-3)...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM016276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel